By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Hematology are presented in a new report. According to news originating from Amsterdam, Netherlands, by NewsRx correspondents, research stated, "Antithrombotic drugs like vitamin K antagonists and heparin have been the gold standard for the treatment and prevention of thromboembolic disease for many years. Unfortunately, there are several disadvantages of these antithrombotic drugs: they are accompanied by serious bleeding problems, it is necessary to monitor the therapeutic window, and there are various interactions with food and other drugs."
Our news journalists obtained a quote from the research from the University of Amsterdam, "This has led to the development of new oral anticoagulants, specifically inhibiting either thrombin or factor Xa. In terms of effectiveness, these drugs are comparable to the currently available anticoagulants; however, they are still associated with issues such as bleeding, reversal of the drug and complicated laboratory monitoring. Vitamin K antagonists, heparin, direct thrombin and factor Xa inhibitors have in common that they target key proteins of the haemostatic system. In an attempt to overcome these difficulties we investigated whether the intrinsic coagulation factors (VIII, IX, XI, XII, prekallikrein and high-molecular-weight kininogen) are superior targets for anticoagulation. We analysed epidemiological data concerning thrombosis and bleeding in patients deficient in one of the intrinsic pathway proteins. Furthermore, we discuss several thrombotic models in intrinsic coagulation factor-deficient animals."
According to the news editors, the research concluded: "The combined results suggest that intrinsic coagulation factors could be suitable targets for anticoagulant drugs."
For more information on this research see: Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? Thrombosis and Haemostasis, 2013;110(2):223-232. Thrombosis and Haemostasis can be contacted at: Schattauer Gmbh-Verlag Medizin Naturwissenschaften, Holderlinstrasse 3, D-70174 Stuttgart, Germany (see also Hematology).
The news correspondents report that additional information may be obtained from M.L. van Montfoort, University of Amsterdam, Academy Med Center, Dept. of Expt Vasc Med, NL-1105 AZ Amsterdam, Netherlands.
Keywords for this news article include: Europe, Heparin, Therapy, Thrombin, Amsterdam, Hematology, Netherlands, Peptide Hydrolases, Enzymes and Coenzymes, Serine Endopeptidases, Blood Coagulation Factors
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC